Fig. 2
From: Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
Cytotoxicity of different PA variants in comparison with PAwt-sANTXR-Ac2. a Viability assay of Flp-In 293-EpCAM-BirA with respective concentrations of PAwt-sANTXR-Ac2, PAm-sANTXR-Ac2, PAm-Ac2, PAwt-Ac2, and PAwt (n = 3). Error bars indicate SEM. b Competition assay with Ac2 DARPin and 100 nM PAm-Ac2 with increasing amounts of competitor Ac2-Flag (n = 3). Error bars indicate SEM. c Quantification of propidium iodide (PI)-positive Flp-In 293-EpCAM-BirA cells during time-lapse imaging, cells treated with either PAwt-sANTXR-Ac2 (black squares) or PAm-Ac2 (green circles) (n = 6). Error bars indicate SEM. d PI (red) staining for permeable cells and LFN-eGFP staining (green) for binding to surface PA, comparing PAwt-sANTXR-Ac2 and PAm-Ac2 on Flp-In 293-EpCAM-BirA cells